The recent studies have explored the physiological effects of GLP-1RA on body organs, establishing them as a potential therapeutic option for a wide range of diseases
They may also help reduce risks related to cardiovascular disease, hypertension, dyslipidemia, and obstructive sleep apnea
The companies that worked on this, then, in the 70s, the 80s, included Lilly and Novo, actually, but it wasnt until the Gila monster story kicked in in the late 80sI think this guy named John Eng in the Bronx was interested in why certain animals didnt need to eat very often and identified this mimic of the human peptide, but used for this lizards own purposes, exendin, which mimics GLP-1
State Medicaid programs and manufacturers were requested to submit their intentions to participate by January 8, 2026, and the model is expected to begin in May 2026
Its extended half-life of approximately 4.7 days is attributed to its structural design, discussed in the large molecule conjugation section of this paper
